85 research outputs found
Reply to the letter "Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients"
No full textPET/MRI in gynecological tumors
No full textThe diagnostic approach to gynecological tumors includes anatomical and molecular imaging methods, representing a strong support for clinicians to define tumor extension, to plan the best treatment strategy and patient management. The possibility of combining morphological and functional information in a single examination, using hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) technique, represents a very promising tool in the different settings of gynaecologic tumors. In the present review, the current literature and potential clinical applications of PET/MRI in the most common types of gynecological tumors are discussed. The role of PET/MRI is in staging, restaging and after treatment of gynecological tumors is presented, focusing on cervical, endometrial and ovarian cancer. Moreover, the diagnostic accuracy of PET/MRI and the correlation between quantitative parameters (standardized uptake value and apparent diffusion coefficient) of PET/MRI hybrid systems are briefly reviewed
Follow-up a 5 anni di bambini con reflusso vescico-ureterale: valutazione mediante scintigrafia renale statica (DMSA-Tc99m)
No full text
Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: A real-life experience from a monocentric cohort
No full textObjectives: To evaluate effectiveness and safety of infliximab dose escalation in Takayasu arteritis (TAK) patients. To identify factors associated with refractoriness to standard-dose infliximab.Methods: Medical records of infliximab-treated TAK patients from a large single-centre observational cohort were reviewed. Infliximab therapy duration, concomitant therapies, and reasons for dose escalation and therapy suspension were evaluated. Occurrence of adverse events was recorded. A comparison between patients who maintained infliximab standard-dose and those who needed dose-escalation was performed. Factors associated with refractoriness to standard dose were analysed.Results: Forty-one patients were included. Starting infliximab dose was 5 mg/kg 6-weekly and 28 patients (68%) needed dose escalation. Persistence/recurrence of clinical symptoms was the most frequent reason for escalation. Median therapy duration was 39 (IQR, 26-61) months in the standard-dose group and 68 (38-87) months in the intensified-dose group. In the intensified-dose-group, infliximab was suspended in eight patients (29%) after a median of 38 (31-71) months, due to loss of response (n= 7) or patient's request (n= 1). Patients in the intensifieddose group had a higher number of relapses (3.4 vs 0.8 events/patient) and received a higher cumulative steroid dose (1.7 [1.6-2.3] vs 1.3 [1-1.6] g/month of prednisone). Three patients from the intensified-dose group had serious infections; one patient from the standard-dose group developed paradoxical psoriasis. At univariate analysis, age at diagnosis and age at infliximab start were associated with infliximab escalation.Conclusion: In TAK, dose escalation is safe and allows to optimise infliximab durability in refractory patients. Younger patients seem to be more refractory to standard dosages
Incidental detection by [C-11]choline PET/CT of meningiomas in prostate cancer patients
No full textAim Anti-androgenic hormonal therapy in prostate cancer patients with concomitant meningioma may result m tumor growth and development of neurological symptoms. Positron emission tomography/computed tomography (PET/CT) with [C-11]choline is used for restaging prostate cancer patients with biochemical failure. In vitro and in vivo data support altered choline metabolism in meningiomas. Methods. During a retrospective study in prostate cancer patients with biochemical failure referred to our institution between November 2004 and Ja-nuary 2007, encephalic focal uptake of [C-11]choline was incidentally noted in 4 patients, 2 of which had been taking luteinizing hormone-releasing hormone analogs. Results. Subsequent to the incidental finding, one patient underwent surgical removal of the meningioma; strict neuroradiological follow-up was planned for the 3 other patients. Conclusion. We suggest that in prostate cancer patients candidate for anti-androgenic therapy the whole body [C-11]choline PET/CT scan should include the whole skull to check for the possible presence of meningiomas. This could help to identify patients at risk for the development of neurological symptoms during anti-androgenic therapy and help the referring urologist in the clinical management of these patients
Comparison of [C-11]Choline PET/CT and bone scintigraphy in the detection of bone metastasis in patients with biochemical failure after primary treatment for prostate cancer
No full textPSMA PET in brain metastases: navigating diagnostic challenges– a thorough exploration
No full textPSMA imaging is gaining importance in the field of oncology, both for diagnostic and therapeutic purposes. In this review, we aimed to highlight the significance of detecting brain metastases from prostate carcinoma before the onset of symptoms, also considering potential pitfalls and false-positive findings. To emphasize this aspect, we present a case report in which the use of an extended field of view to the vertex allowed to the localization of brain lesions before the onset of symptoms. The present clinical report describe the rare case of brain metastases from prostate carcinoma detected by [18F]F-PSMA-1007 PET/CT
- …
